OCT guided vs. COmplete pci in patieNts with sT segment elevation myocArdial infarCtion and mulTivessel disease: OCT-CONTACT RCT

医学 传统PCI 心脏病学 经皮冠状动脉介入治疗 心肌梗塞 内科学 狼牙棒 罪魁祸首 部分流量储备 随机对照试验 血运重建 临床终点 冠状动脉造影
作者
Mario Iannaccone,Ovidio De Filippo,Andrea Montabone,Giorgio Marengo,Ludovica Maltese,Fabrizio Ugo,Giorgio Quadri,Maro MENNUNI,Gioel Gabrio Secco,Vittorio Taglialatela,Sebastian Cinconze,Claudio Moretti,Alessandra Truffa,Alfonso Gambino,Giacomo Boccuzzi,Vincenzo Infantino,Federico Conrotto,Alessandro Lupi,Ferdinando Varbella,Giuseppe Patti
出处
期刊:Minerva cardiology and angiology [Edizioni Minerva Medica]
卷期号:71 (4) 被引量:4
标识
DOI:10.23736/s2724-5683.22.06144-0
摘要

In patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the culprit lesion significantly reduces the risk of cardiovascular death. However, the management of non-culprit lesions in patients with the multivessel disease remains a matter of debate in this setting. It's still unclear if a morphological OCT-guided approach, identifying coronary plaque instability, may provide a more specific treatment compared with a standard angiographic/functional approach.OCT-Contact is a prospective, multicenter, open-label, non-inferiority randomized controlled trial. Patients with STEMI with successful primary PCI of the culprit lesion will be enrolled after the index PCI. Patients will be deemed eligible if a critical coronary lesion other than the culprit (associated with a diameter of stenosis ≥50%) will be identified during the index angiography. Patients will be randomized in a 1:1 fashion to OCT-guided PCI of non-culprit lesions (Group A) vs. complete PCI (Group B). PCI in group A will be undertaken according to criteria of plaque vulnerability, while in group B the use of fractional flow reserve will be left at the operators' discretion. Major-adverse cardiovascular events (MACE) are a composite of all-cause mortality, non-fatal myocardial infarction (MI) (excluding peri-procedural MI), unplanned revascularization, and NYHA IV heart failure) will be the primary efficacy outcome. Single components of MACE along with cardiovascular mortality will be the secondary endpoints. . Safety endpoints will embrace worsening of renal failure, procedural complications, and bleedings. Patients will be followed for 24 months after randomization.A sample size of 406 patients (203 per group) is required to provide the analysis an 80% power to detect a non-inferiority in the primary endpoint with an alpha error set at 0.05 and a non-inferiority limit of 4%.A morphological OCT-guided approach may be a more specific treatment compared with the standard angiographic/functional approach in non-culprit lesions of STEMI patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
dd关闭了dd文献求助
刚刚
雨季完成签到,获得积分10
1秒前
1秒前
Dong发布了新的文献求助10
1秒前
2秒前
小蘑菇应助少年采纳,获得10
2秒前
3秒前
3秒前
思源应助饱满怀梦采纳,获得10
3秒前
handsome发布了新的文献求助10
3秒前
高哈哈哈完成签到,获得积分10
3秒前
工藤应助欢呼夏青采纳,获得15
3秒前
个性的夜白完成签到,获得积分10
4秒前
5秒前
5秒前
元谷雪发布了新的文献求助10
6秒前
maguodrgon发布了新的文献求助30
6秒前
王怡凡发布了新的文献求助10
6秒前
英姑应助lkz采纳,获得10
6秒前
领导范儿应助小陈采纳,获得10
8秒前
慈祥的惜梦应助Zoe采纳,获得10
8秒前
熊猫海发布了新的文献求助10
9秒前
10秒前
Gorone发布了新的文献求助20
11秒前
充电宝应助lkz采纳,获得10
12秒前
13秒前
14秒前
闫伟伟发布了新的文献求助10
14秒前
0994完成签到,获得积分10
14秒前
曲阿完成签到 ,获得积分10
15秒前
甜虾完成签到,获得积分10
15秒前
希望天下0贩的0应助Saliyan采纳,获得10
15秒前
顺顺利利完成签到,获得积分10
15秒前
medlive2020发布了新的文献求助10
15秒前
16秒前
17秒前
浮生寄旧梦完成签到,获得积分10
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Developing Genetic Editing Tools for Lysobacter 2000
卤化钙钛矿人工突触的研究 2000
Моделирование процессов самоорганизации в кристаллообразующих системах 1000
History of U.S. Space Surveillance and Satellite Cataloging 1000
Adhesion Science: Principles & Practice 800
Signals, Systems, and Signal Processing 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6520287
求助须知:如何正确求助?哪些是违规求助? 8313288
关于积分的说明 17780155
捐赠科研通 5622418
什么是DOI,文献DOI怎么找? 2927083
邀请新用户注册赠送积分活动 1903985
关于科研通互助平台的介绍 1764368